As pharmaceutical and life sciences organisations increasingly outsource regulated activities, vendor oversight has become a critical focus area for regulators. Activities governed by Good Manufacturing Practice (GMP) and pharmacovigilance (PV) are frequently delegated to third parties, yet accountability for compliance, data integrity, and patient safety always remains with the contracting organisation. Vendor audit programmes therefore play a central role in demonstrating control and regulatory maturity.
Health authorities such as the MHRA and EMA expect companies to maintain structured, risk-based vendor audit programmes that are fully embedded within their quality and pharmacovigilance systems. During inspections, auditors are not only interested in whether vendor audits are conducted, but whether they are meaningful, proportionate, and followed through to completion.
Read More: QPPV Services for MAHs: Defining Real Oversight in Outsourced PV Models
Regulatory Expectations for Vendor Oversight
Both GMP and GVP legislation clearly require organisations to ensure that outsourced activities are performed in accordance with applicable regulatory requirements. Inspectors consistently assess whether vendor oversight is active rather than reactive and whether companies can demonstrate continuous monitoring of third-party compliance.
Regulators expect vendor audit programmes to show:
- Clear ownership and accountability for outsourced activities
- A documented and risk-based audit strategy
- Evidence of audit execution and follow-up
- Integration with the wider Quality Management System (QMS) or Pharmacovigilance System
A lack of formalised vendor auditing or reliance solely on contractual assurances is often viewed as a serious compliance gap.
Defining the Scope of Vendor Audits
An effective vendor audit programme begins with a clear understanding of the vendor landscape. Regulators expect organisations to identify all third parties whose activities may impact product quality, patient safety, or regulatory compliance and to define audit scope accordingly.
Vendor categories commonly included within scope are:
- Contract Manufacturing Organisations (CMOs)
- Contract Research Organisations (CROs)
- Pharmacovigilance service providers
- Laboratories and testing facilities
- IT vendors supporting GMP or PV systems
The rationale for inclusion or exclusion of vendors must be documented, typically through formal risk assessments. Inspectors frequently challenge organisations that are unable to justify why certain vendors are not subject to audit.
Applying a Risk-Based Approach to Vendor Audits
A risk-based approach is fundamental to regulatory expectations and should drive both audit frequency and depth. Regulators do not expect uniform auditing of all vendors but do expect a logical, defensible approach aligned with regulatory risk.
Key risk factors considered include:
- Criticality of the outsourced activity
- Potential impact on patient safety or product quality
- Complexity of processes and systems
- Vendor compliance history and inspection outcomes
High-risk vendors require more frequent, in-depth audits, while lower-risk vendors may be subject to alternative oversight measures, provided this approach is justified and documented.
Audit Planning, Scheduling, and Governance
Vendor audits should be planned proactively through a documented audit schedule, often covering multiple years. Regulators expect audit plans to be reviewed periodically and updated in response to changes in risk, vendor performance, or regulatory requirements.
Effective audit governance typically includes:
- A rolling audit plan approved by management
- Defined audit objectives and scope
- Clear escalation pathways for critical findings
- Management visibility of audit outcomes
Inspectors frequently assess whether audit results are discussed at governance forums and whether senior management is engaged in addressing significant risks.
Auditor Qualification and Independence
The quality of vendor audits is closely linked to the competence and independence of the auditors. Regulators expect audits to be conducted by individuals with appropriate GMP or PV expertise and sufficient understanding of applicable regulatory requirements.
Auditor expectations include:
- Documented qualifications, training, and experience
- Independence from the audited activities
- Ongoing competency maintenance
- Relevant technical expertise for the audit scope
While external auditors may be used, accountability for audit quality and outcomes remains with the contracting organisation.
Conducting Effective Vendor Audits
Regulators assess not only whether audits occur but also how they are conducted. Vendor audits should go beyond superficial document review and evaluate how systems operate in practice.
Effective audits typically involve:
- Review of quality or pharmacovigilance management systems
- Assessment of SOPs, records, and data integrity controls
- Interviews with key vendor personnel
- Verification of compliance with contractual and regulatory requirements
Audits that focus solely on checklists without critical evaluation often fail to meet inspection expectations.
Audit Reporting and CAPA Management
Audit reports are key inspection artefacts and must accurately reflect the audit scope, findings, and conclusions. Regulators expect reports to be clear, timely, and objective, with findings appropriately classified according to risk.
Effective CAPA management includes:
- Timely agreement of corrective and preventive actions
- Root cause analysis linked to audit findings
- Defined timelines and ownership
- Verification of CAPA effectiveness
Failure to adequately follow up on audit findings is a common regulatory observation and can undermine the credibility of the vendor audit programme.
Integration with Quality and Pharmacovigilance Systems
Vendor audit programmes should be fully integrated into the organisation’s Quality Management System and Pharmacovigilance System. Regulators expect audit outcomes to inform risk management, continuous improvement, and management review processes.
This integration enables:
- Trending and analysis of recurring audit findings
- Identification of systemic issues across vendors
- Proactive risk mitigation and escalation
- Improved inspection readiness
A mature audit programme supports long-term compliance rather than reactive remediation.
How Quality and Vigilance Ltd Can Support Vendor Audit Programmes
Quality and Vigilance Ltd provides expert support for GMP and pharmacovigilance vendor audit programmes, helping organisations meet regulatory expectations with confidence. Their experienced auditors and consultants bring strong UK and EU regulatory knowledge, supported by practical inspection experience.
Quality and Vigilance Ltd supports organisations by:
- Designing and implementing risk-based vendor audit programmes
- Conducting independent GMP and PV vendor audits
- Supporting audit reporting and CAPA management
- Enhancing inspection readiness and regulatory confidence
By partnering with Quality and Vigilance Ltd, organisations can strengthen vendor oversight, reduce compliance risk, and demonstrate the level of control that regulators expect in an increasingly outsourced pharmaceutical environment.